Výsledky vyhledávání - "Hsiao-Wang Cheng"

Dissertation/ Thesis

A Rresearch for Implementing the ERP Impact on the Business - Using Company J in Taiwan as Example

Autor: Hsiao-Wang Cheng, 鄭孝望

100
In the process of enterprise development, with the growth of revenue and organization, units inside an organization need faster communication and coordination to cope with the fierce competition of globalization. This includes the timing of

Externí odkaz: http://ndltd.ncl.edu.tw/handle/07617175199126691488

Zobrazit plný text záznamu

Effect of PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, on proliferation in renal cell carcinoma at nanomolar concentrations and prediction of sensitivity by molecular markers

Autor: Dylan Conklin, Joshua E. Logan, Dennis J. Slamon, Amrita J. Desai, Mark A. Eckardt, James G. Christensen, Erika Von Euw, Arie S. Belldegrun, Veerauo Konkatkit, Eileen Taschereau, Nikayeh Mostofizadeh, Hsiao-Wang Cheng, Charles Ginther, Fairooz F. Kabbinavar, Habib Hamidi, Lee Anderson

Publikováno v: Journal of Clinical Oncology. 31:413-413

413 Background: Cell cycle dysregulation is prevalent in renal cell carcinoma (RCC). PD-0332991 is an orally active, potent, and selective inhibitor of cyclin-dependent kinases (CDK) 4 and 6, blocking retinoblastoma (Rb) phosphorylation at nanomolar

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2947eda11dff411883104c13ed6ee7bd
https://doi.org/10.1200/jco.2013.31.6_suppl.413

Zobrazit plný text záznamu

Molecular profiling and comparative genomic hybridization analysis in human melanoma cell lines and identification of BRAF amplification in a PLX4032 acquired resistance cell line

Autor: Hsiao-Wang Cheng, Charles Ginther, Dennis J. Slamon, Lee Anderson, Erika von Euw, Richard S. Finn, Judy Dering, Veerauo Konkankit, Ke Wei Gong

Publikováno v: Journal of Clinical Oncology. 30:8592-8592

8592 Background: Melanoma is the most aggressive form of skin cancer. Its management is evolving rapidly due to an improved understanding of the molecular heterogeneity and the development of effective, personalized targeted therapies. PLX4032 is a B

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::88c56fbc173a4426e628dc4b3cf03f86
https://doi.org/10.1200/jco.2012.30.15_suppl.8592

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání